An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue
Latest Information Update: 09 Jun 2021
At a glance
- Drugs Dengue tetravalent vaccine Takeda (Primary)
- Indications Dengue
- Focus Pharmacodynamics; Registrational
- Sponsors Takeda
Most Recent Events
- 06 Apr 2020 Status changed from active, no longer recruiting to completed.
- 20 Nov 2019 Planned End Date changed from 16 Mar 2020 to 20 Mar 2020.
- 20 Jun 2019 Planned End Date changed from 20 Dec 2019 to 16 Mar 2020.